PYC Therapeutics Limited (PYC.AX)
| Previous close | 0.0650 |
| Open | 0.0660 |
| Bid | 0.0650 x 42340100 |
| Ask | 0.0750 x 21464600 |
| Day's range | 0.0650 - 0.0730 |
| 52-week range | 0.0610 - 0.1600 |
| Volume | |
| Avg. volume | 661,294 |
| Market cap | 209.941M |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
PYC Therapeutics Announces Upcoming Poster Presentations Highlighting Preclinical Data from its Ocular and Neurologic Development Programs at TIDES USA and OTS 2021
PYC Therapeutics (ASX: PYC), a biotechnology company combining two complementary platform technologies (selective drug delivery and precision drug design) to develop a new generation of RNA therapeutics to change the lives of patients with inherited diseases, today announced two upcoming virtual poster presentations highlighting preclinical data from its ocular and neurologic development programs. The first poster will be presented at TIDES USA 2021, an Oligonucleotide and Peptide Therapeutics c
- PR Newswire
PYC Therapeutics Invited to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
PYC Therapeutics (ASX: PYC), a biotechnology company combining two complementary platform technologies (selective drug delivery and precision drug design) to develop a new generation of RNA therapeutics to change the lives of patients with inherited diseases, today announced it will participate as one of a select group of companies at the upcoming Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, taking place virtually on September 20–23, 2021.
- PR Newswire
PYC Therapeutics Assembles Ophthalmology-Focused Clinical Advisory Board
PYC Therapeutics (ASX: PYC), a biotechnology company combining two complementary platform technologies (selective drug delivery and precision drug design) to develop a new generation of RNA therapeutics to change the lives of patients with inherited diseases, today announced the formation of its ophthalmology-focused Clinical Advisory Board. The Advisory Board will work closely with the Company's executive management team to support the advancement of its rich pipeline of therapeutic candidates
